The global Generic Drugs market accounted for USD 515.0 billion in 2020 and is expected to reach USD 1,042.1 billion by 2028, growing at a CAGR of around 9.4% between 2021 and 2028.
Market Overview
The global Generic Drugs market accounted for USD 515.0 billion in 2020 and is expected to reach USD 1,042.1 billion by 2028, growing at a CAGR of around 9.4% between 2021 and 2028.
Pharmacology is the study of drugs and medicines, including their uses, effects, and characteristic. Generic drugs are chemically identical to their branded counterparts. Although, generic drugs are bioequivalent to branded drugs, they are sold at the significant discount from branded drugs prices. As per the FDA approval, the generic drug should contain the same active ingredient as their branded counterpart; it should be bioequivalent and should meet batch requirements for identity, quality, purity, and strength. It should be identical on the route of administration and dosage form. It should be manufactured under the same rules and regulation of FDA’s good manufacturing practice required for branded drugs. Generic drugs manufacturing companies are capable of selling generic drugs at the lower price because they are not required to repeat costly clinical trials and pay for marketing and promotion strategies.
India is the largest provider of generic drugs across the globe. Pharmaceutical sector in India supplies over 50% of global demand for various vaccines, 40% of generic demand in the US and 25% of all medicine in the UK. India ranks 3rd in terms of production of various Pharma medicines by volume and 14th by value.
COVID-19 Impact Analysis:
The pandemic has led to increase the demand for drugs and APIs, those used against malaria are most in the demand and then antibiotics and antivirals. A second wave of deficiency is observed among various diseases patients which is needed to care. As the pandemic progresses, the manufacturer of generic drugs work around the clock to ensure American patients have access to drugs they need.
The covid-19 has created an opportunity for the numbers of patients as there is high chances of adverse health effects of covid-19 on the people. However, the covid-19 has positively impacted on the generic drugs market.
Growth Factors
Globally, the market for the generic drug has been propelled by new government initiatives to produce generic drugs and mainly to promote the use of generic drugs against chronic diseases. Patent expiration of branded drugs is one of the key influencers for the growth and prime reason for generating more revenue for generic drugs market. Moreover, new emerging markets of developing countries and low cost of generic drugs are majorly responsible for thickening the growth of generic drugs market. In spite of this, the market is affected by high competition within the globe and it is due to, economic expenditure required for the production of generic drugs is the very low thus number of leading companies taking interest in the production of generic drugs. In future, new developing and uncovered markets may responsible for the generation of new opportunities.
Report Scope:
Report Attribute | Details |
---|---|
Base Year | 2020 |
Historic Years | 2016 - 2020 |
Forecast Years | 2021 - 2028 |
Segments Covered | By Product Type, By Application, and By End Use |
Forecast Units | Value (USD Billion), and Volume (Units) |
Quantitative Units | Revenue in USD million/billion and CAGR from 2021 to 2028 |
Regions Covered | North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, and Rest of World |
Countries Covered | U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others |
Number of Companies Covered | 10 companies with scope for including additional 15 companies upon request |
Report Coverage | Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis, and COVID-19 impact analysis. |
Customization Scope | Avail customized purchase options to meet your exact research needs. |
Segment Analysis Preview
Based on the various types of Generic Drugs, the global Generic Drugs market is segmented into pure generic drugs and Branded generic drugs.
The market of the generic drug has been segmented on the basis of the brand as pure generic drug and branded generic drugs. Branded generic drugs are marketed under another company’s brand name but they are bioequivalent to their generic counterparts. Due to high involvement of companies in manufacturing pure generic drugs, pure generic drug segment is dominating the market.
Application Analysis Preview
Based on the application the market of generic drugs has been segmented as central nervous system (CNS), cardiovascular, dermatology, oncology, respiratory and others. With more than 20.5% revenue contribution, the cardiovascular segment was leading the generic drug market in 2020 due to a number of patent expiries of cardiovascular drugs. With more than 15.2% revenue contribution, central nervous system (CNS) will show significant growth in the forecast period.
Regional Preview
North America is dominating the generic drug market due to high demand and increasing the prevalence of chronic diseases. Asia-Pacific is expected to show good growth in the forecast period. In Asia Pacific, India and China are leading countries in the genetic drug market.
Key Market Players & Competitive Landscape
The major players operating Generic Drugs market are Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., Abbott Healthcare Pvt. Ltd., Actavis Pharmaceuticals and Sun Pharmaceuticals.
The global Generic Drugs market is segmented as follows:
By Brand
By Applications
By Region
List of Figures
FIG NO. 1. Market Attractiveness Analysis, By Brand
FIG NO. 2. Market Attractiveness Analysis, By Application
FIG NO. 3. Market Attractiveness Analysis, By Region
FIG NO. 4. Global Generic Drugs Market Revenue, 2016 – 2028 (USD Billion)
FIG NO. 5. Impact of COVID-19 Pandemic in North America Countries
FIG NO. 6. Market Revenue Share, By Brand, 2020 & 2028
FIG NO. 7. Global Generic Drugs Market for Pure generic drugs, Revenue (USD Billion) 2016 – 2028
FIG NO. 8. Comparative Revenue Analysis of Generic Drugs Market for Pure generic drugs, By Country, 2020 & 2028
FIG NO. 9. Global Generic Drugs Market for Branded generic drugs, Revenue (USD Billion) 2016 – 2028
FIG NO. 10. Comparative Revenue Analysis of Generic Drugs Market for Branded generic drugs, By Country, 2020 & 2028
FIG NO. 11. Global Generic Drugs Market for Oncology, Revenue (USD Billion) 2016 – 2028
FIG NO. 12. Comparative Revenue Analysis of Generic Drugs Market for Oncology, By Country, 2020 & 2028
FIG NO. 13. Global Generic Drugs Market for Respiratory, Revenue (USD Billion) 2016 – 2028
FIG NO. 14. Comparative Revenue Analysis of Generic Drugs Market for Respiratory, By Country, 2020 & 2028
FIG NO. 15. Global Generic Drugs Market for Others, Revenue (USD Billion) 2016 – 2028
FIG NO. 16. Comparative Revenue Analysis of Generic Drugs Market for Others, By Country, 2020 & 2028
FIG NO. 17. Market Revenue Share, By Application, 2020 & 2028
FIG NO. 18. Global Generic Drugs Market for Central nervous system (CNS), Revenue (USD Billion) 2016 – 2028
FIG NO. 19. Comparative Revenue Analysis of Generic Drugs Market for Central nervous system (CNS), By Country, 2020 & 2028
FIG NO. 20. Global Generic Drugs Market for Cardiovascular, Revenue (USD Billion) 2016 – 2028
FIG NO. 21. Comparative Revenue Analysis of Generic Drugs Market for Cardiovascular, By Country, 2020 & 2028
FIG NO. 22. Global Generic Drugs Market for Dermatology, Revenue (USD Billion) 2016 – 2028
FIG NO. 23. Comparative Revenue Analysis of Generic Drugs Market for Dermatology, By Country, 2020 & 2028
FIG NO. 24. Global Generic Drugs Market for Oncology, Revenue (USD Billion) 2016 – 2028
FIG NO. 25. Comparative Revenue Analysis of Generic Drugs Market for Oncology By Country, 2020 & 2028
FIG NO. 26. Global Generic Drugs Market for Oncology, Revenue (USD Billion) 2016 – 2028
FIG NO. 27. Comparative Revenue Analysis of Generic Drugs Market for Oncology, By Country, 2020 & 2028
FIG NO. 28. Global Generic Drugs Market Revenue Share, By Region, 2020 & 2028
FIG NO. 29. North America Generic Drugs Market Revenue, 2016 - 2028 (USD Billion)
FIG NO. 30. Porter’s Five Forces Analysis for Global Generic Drugs Market
FIG NO. 31. PEST Analysis for Global Generic Drugs Market
FIG NO. 32. Pricing Analysis for Global Generic Drugs Market
FIG NO. 33. Value Chain Analysis for Global Generic Drugs Market
FIG NO. 34. Company Share Analysis, 2019
FIG NO. 35. Radar Determinant Chart, 2019
FIG NO. 36. Company Strategic Developments – Heat Map Analysis
FIG NO. 37. Teva Pharmaceutical Industries Ltd Business Segment Revenue Share, 2020 (%)
FIG NO. 38. Teva Pharmaceutical Industries Ltd Geographical Segment Revenue Share, 2020 (%)
FIG NO. 39. Market Channels
FIG NO. 40. Marketing Channel Development Trend
FIG NO. 41. Growth in World Gross Product, 2008-2018
FIG NO. 42. Research Methodology – Detailed View
FIG NO. 43. Research Methodology
List of Tables
TABLE NO. 1. Global Generic Drugs Market: Snapshot
TABLE NO. 2. Quarterly Generic Drugs Market Revenue by Region, 2020
TABLE NO. 3. Quarterly Generic Drugs Market Revenue Forecast by Region, 2021
TABLE NO. 4. Pre COVID-19 Market Revenue, By Region, 2016-2019 (USD Billion)
TABLE NO. 5. Post COVID-19 Market Revenue, By Region, 2020-2028 (USD Billion)
TABLE NO. 6. Global Generic Drugs Market for Pure generic drugs, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 7. Global Generic Drugs Market for Branded generic drugs, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 12. Global Generic Drugs Market for Oncology, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 13: Global Generic Drugs Market for Central nervous system (CNS), by Region, 2016 – 2028 (USD Billion)
TABLE NO. 14: Global Generic Drugs Market for Cardiovascular, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 15. Global Generic Drugs Market for Dermatology, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 16. Global Generic Drugs Market for Oncology, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 17. Global Generic Drugs Market for Respiratory, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 18. Global Generic Drugs Market for Others, by Region, 2016 – 2028 (USD Billion)
TABLE NO. 19. Global Generic Drugs Market Revenue, By Region, 2016 – 2028 (USD Billion)
TABLE NO. 20: North America Generic Drugs Market Revenue, By Country, 2016 – 2028 (USD Billion)
TABLE NO. 21. North America Generic Drugs Market Revenue, By Brand, 2016 – 2028 (USD Billion)
TABLE NO. 22: North America Generic Drugs Market Revenue, By Application, 2016 – 2028 (USD Billion)
TABLE NO. 23. U.S. Generic Drugs Market Revenue, By Brand, 2016 – 2028 (USD Billion)
TABLE NO. 24. U.S. Generic Drugs Market Revenue, By Application, 2016 – 2028 (USD Billion)
TABLE NO. 25. Canada Generic Drugs Market Revenue, By Brand, 2016 – 2028 (USD Billion)
TABLE NO. 26. Canada Generic Drugs Market Revenue, By Application, 2016 – 2028 (USD Billion)
TABLE NO. 27. Mexico Generic Drugs Market Revenue, By Brand, 2016 – 2028 (USD Billion)
TABLE NO. 28: Mexico Generic Drugs Market Revenue, By Application, 2016 – 2028 (USD Billion)
TABLE NO. 29 Drivers for the Generic Drugs Market: Impact Analysis
TABLE NO. 30. Restraints for the Generic Drugs Market: Impact Analysis
TABLE NO. 31. Major Buyers of Generic Drugs
TABLE NO.32: Distributors/Traders List of Generic Drugs
TABLE NO. 33. Global Generic Drugs Market, Company Market Revenue, 2016 – 2019 (USD Billion)
TABLE NO. 34: Global Generic Drugs Market, Company Y-o-Y Growth, 2017 – 2019 (USD Billion)
The report covers forecast and analysis for the Generic Drug market on a global and regional level. The study provides historic data of 2015 along with a forecast from 2016to 2026 based revenue (USD Billion). The study includes drivers and restraints for the Generic Drug market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the generic drug market on a global level.
Pharmacology is the branch of biology, which deals with the study of drugs, their properties, and their sources. Generic drugs are bioequivalent to branded drugs in quality, dosage form, strength, intended use and route of administration. After the expiry of the patent, same branded drug can be copied and manufactured by any other manufacturer at an affordable cost. The most important advantage of generic drugs is they are less expensive as compared to branded drugs because they are not required to repeat costly clinical trials and pay for marketing, advertising and for promotion. As per FDA rules and regulation for substitution of branded drugs, generic drugs should have the same active ingredient, same administration route, same dosage strength, and form. Nowadays, plenty of anti-diabetic, anti-hypersensitive and antibiotic drugs are available in generic formulations.
The market for the generic drug has been accelerated by increasing number of patent expiration of branded drugs and government initiatives. Moreover, increasing the prevalence of chronic diseases and emerging markets are responsible for the growth of generic drugs market. Furthermore, decreased the cost of the drug is acting as a most important factor for the growth of generic drug market. However, high competition and the shortage of drugs can restrict the growth of generic drug market. In addition, prescription of doctors is largely affecting the growth of generic drug market because doctors are prescribing branded drugs to their patient. However, an untapped and emerging market like India and China are expected to generate more opportunities for generic drug market in the forecast period.
Based on the brand classification, generic drug market is segmented as pure generic and branded generic. Branded generic drugs are bioequivalent to the generic drugs, but the difference is they are marketed under another companies brand names. Pure generic drugs segment is dominating the market with high market share.
Based on therapeutic application, the market is segmented as central nervous system (CNS), cardiovascular, dermatology, oncology, respiratory and others. CNS and Cardiovascular segments are the two largest market segment covered by generic drug market. The cardiovascular segment covers more than 20% of global generic drug market due to a number of patent expiries of cardiovascular drugs. Central Nervous System (CNS) is also an emerging segment with more than 16.5 % revenue contribution for the year 2018.
Based on the geography, the market has been segmented into North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa. North America is dominating the generic drug market due to high demand and increasing the prevalence of chronic diseases. Asia-Pacific is expected to show noticeable growth during the forecast period. In Asia Pacific, India and China are leading countries in the genetic drug market.
Key operating players for generic drugs market are Teva Pharmaceutical Industries Ltd., Novartis International AG, Mylan N.V., Abbott Healthcare Pvt. Ltd., Actavis Pharmaceuticals and Sun Pharmaceuticals
Request the coronavirus impact analysis across industries and markets
The global Generic Drugs Market was valued at USD 515.0 Billion in 2020.
The global Generic Drugs Market is expected to reach USD 1,042.2 Billion by 2028, growing at a CAGR of 9.4% between 2021 to 2028.
Some of the key factors driving the global Generic Drugs Market growth are new government initiatives to produce generic drugs and mainly to promote the use of generic drugs against chronic diseases.
North America is dominating the generic drug market due to high demand and increasing the prevalence of chronic diseases. Asia-Pacific is expected to show good growth in the forecast period.
Zion Market Research
Tel: +1 (844) 845-5245
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No 020-46277770
US OFFICE NO +1 (844) 845-5245
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed